Safety of tocilizumab in the treatment of juvenile idiopathic arthritis

Expert Opinion on Drug Safety

Volumn 16, Issue 4, 2017, Pages 493-500

  Machado, Sandra Helena ^a   Xavier, Ricardo Machado ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

IL 6 inhibitors; juvenile idiopathic arthritis; safety; treatment

Indexed keywords

BIOLOGICAL PRODUCT; TOCILIZUMAB; ANTIRHEUMATIC AGENT; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; ARTICLE; BACTERIAL PNEUMONIA; BRONCHITIS; CELLULITIS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; GASTROENTERITIS; GASTROINTESTINAL INFECTION; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; INFUSION RELATED REACTION; INTRACRANIAL HYPERTENSION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; MACROPHAGE ACTIVATION SYNDROME; NEUTROPENIA; PNEUMONIA; POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; THROMBOCYTOPENIA; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; CHEMICALLY INDUCED; CHILD; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; HUMANS; RECEPTORS, INTERLEUKIN-6; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX;

EID: 85015995798     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1303479     Document Type: Article

References (41)

1. Kahn PJ., Juvenile idiopathic arthritis–what the clinician needs to know. Bull Hosp Jt Dis. 2013;71:194–199.
2. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138–2149. Epub 2011/06/21.
3. Makay B, Unsal E, Kasapcopur O. Juvenile idiopathic arthritis. World J Rheumatol. 2013;12:16–24.
4. Wong SC, MacRae VE, Gracie JA, et al. Inflammatory cytokines in juvenile idiopathic arthritis:effects on physical growth and the insulin-like-growth factor axis. Growth Horm IGF Res. 2008;18:369–378. Epub 2008/04/02.
5. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis:Durban, 1997. J Rheumatol. 1998;25:1991–1994. Epub 1998/10/21.
6. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis:second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392. Epub 2004/02/05.
7. Dueckers G, Guellac N, Arbogast M, et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol. 2012;142:176–193. Epub 2011/12/14.
8. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis:a revolution in care. Pediatr Rheumatol Online J. 2014;12:13. Epub 2014/05/02.
9. Haines KA. Juvenile idiopathic arthritis:therapies in the 21st century. Bull NYU Hosp Jt Dis. 2007;65:205–211. Epub 2007/10/10.
10. Webb K, Wedderburn LR. Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol. 2015;27:505–510. Epub 2015/07/07.
11. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2:288–294. Epub 2014/04/26.•• A very interesting review about the importance of IL-6.
12. Souza LS, Machado SH, Brenol CV, et al. Growth velocity and interleukin 6 concentrations in juvenile idiopathic arthritis. J Rheumatol. 2008:35:2265-2271. Epub 2008/10/10.
13. MacRae VE, Wong SC, Farquharson C, et al. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review). Int J Mol Med. 2006;18:1011–1018. Epub 2006/11/08.
14. Pass C, MacRae VE, Ahmed SF, et al. Inflammatory cytokines and the GH/IGF-I axis:novel actions on bone growth. Cell Biochem Funct. 2009;27:119–127. Epub 2009/03/31.
15. Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53:851–856. Epub 1993/02/15.
16. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol. 2009;21:224–230. Epub 2009/04/15.
17. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61. Epub 1999/12/23.
18. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders:24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72:43–50. Epub 2012/05/09.
19. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–1209. Epub 1997/07/01.
20. Consolaro A, Giancane G, Schiappapietra B, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14:23. Epub 2016/04/20.
21. Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15:931–934. Epub 2016/07/10.
22. Beukelman T. Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep. 2014;6:21. Epub 2014/04/26.
23. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis & Rheumatism. 2005;52(3):818–825.
24. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis:proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8. Epub 2005/11/10.
25. Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012;22:109–115. Epub 2011/06/15.
26. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis:a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006. Epub 2008/03/25.
27. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395. Epub 2012/12/21.•• This considerably relevant trial showed that TCZ was effective in systemic juvenile idiopathic arthritis.
28. Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis:results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–1117. Epub 2014/05/20.•• This is a very important clinical trial demonstrating efficacy in treatment of polyarticular juvenile idiopathic arthritis.
29. Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting:results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654–1660. Epub 2015/12/09.•• This interesting and unique study evaluates adverse events associated with TCZ in a real-world setting in Japan.
30. Horneff G. Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep. 2015;17:66. Epub 2015/09/20.
31. Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis:a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55:669–679. Epub 2015/12/03.
32. Heijstek MW, Ott De Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704–1712. Epub 2011 Aug 3.• It is important to know these recommendations for vaccination in pediatric patients.
33. Groot N, Heijstek MW, Wulffraat NM. Vaccinations in paediatric rheumatology:an update on current developments. Curr Rheumatol Rep. 2015;17:46.
34. Matsui T, Komiya A, Shimada K, et al. Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. Mod Rheumatol. 2009;19:696–697.
35. Hoffmann JJ. Neutrophil CD64:a diagnostic marker for infection and sepsis. Clin Chem Lab Med. 2009;47:903–916.
36. Yokota S, Itoh Y, Morio T, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42:712–722. Epub 2015 Feb 15.
37. Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28:277–292.• This is an excelent review about the phisiopathology of macrophage activation syndrome.
38. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis. 2016;75:68–74. Epub 2015 Jun 8.
39. Kivitz A, Wallace T, Olech E, et al. Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis:a multicenter phase 3b long-term extension study. Rheumatol Ther. 2016;3:291–304. Epub 2016 Sep 24.
40. Liu X, Jones GW, Choy EH, et al. The biology behind interleukin-6 targeted interventions. Curr Opin Rheumatol. 2016;28:152–160.
41. Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36. Epub 2015 Dec 3.